Gryphon Investors-backed Metagenics has acquired probiotic brand Symprove from bd-capital. The deal adds a direct-to-consumer probiotic product to Metagenics' portfolio, which focuses on nutrition and wellness solutions. This move expands Metagenics' reach into the growing gut health market.

The acquisition follows a broader trend of private equity backing in the health and wellness sector. Symprove, a UK-based brand, gains access to Metagenics' distribution and scientific resources. For Gryphon, it’s a strategic play to consolidate assets in a fragmented probiotics space.

Investors should watch for integration plans and how Symprove’s consumer brand will fit alongside Metagenics’ practitioner-focused products. The deal’s value was not disclosed, but it signals continued consolidation in the nutrition industry as companies seek scale and diversified revenue streams.